How profitable is Arcus Biosciences Inc. (RCUS)?

In FY 2025 (10-K), RCUS converted $33.0M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / RCUS / financials

PBH (62) BHVN (44) PHVS (59) HCM (34) ⌘ Pro Terminal →

Arcus Biosciences Inc. (RCUS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$17.85 -1.87% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $17.76

Arcus Biosciences Inc. (RCUS) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $2.32B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RCUS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RCUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Arcus Biosciences Inc. (NYSE: RCUS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $17.85 (-1.87% 1D, market cap $2.32B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RCUS ranks #988 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RCUS compare to PBH and BHVN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RCUS carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PBH (Prestige Consumer Healthcare Inc.) holds a C grade (62/100 RQD, P/E 12.1x, ROIC 13.8%, cap $2.32B) and BHVN (Biohaven Ltd.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $2.33B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RCUS?

▼

Per RCUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001724521), Arcus Biosciences Inc. generated $33.0M in revenue (-35.3% YoY), -$353.0M in net income, and -$484.0M in free cash flow against $1.14B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $17.76 (-0.53%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-17.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RCUS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (19/100 Composite)

🔍 WHY RCUS SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Cash Engine Quality+4/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$22.51+5.5% Next Q

Q2 (-2Q)

Grade E$23.75-23.6% Next Q

Q3 (-1Q)

Grade E$18.14-1.6% Next Q

Current

Grade E$17.85-12% Hist 90D α

Trajectory: E (27) → E (19)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RCUS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RCUS currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.50) and Max Pain ($18.74) forces dealer call-delta covering toward $33.33.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RCUS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RCUS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 19%NO 81%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How RCUS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $37.0M

FY24

Rev $51.0M

FY25

Rev $33.0M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$33.0M	52%	-80%	-$353.0M	-$484.0M	-45%
FY 2024	$51.0M	52%	-80%	-$283.0M	-$176.0M	-45%
FY 2023	$37.0M	52%	-80%	-$307.0M	-$306.0M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RCUS)

✓Walkthrough of RCUS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RCUS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -31.48%📐 HORIZONTAL RANGE

2026-11-03O $18.61H $18.61L $17.85C $17.85VOL 1.94M

RES: $31.38SUP: $16.46SMA50: $24.50SMA200: $24.63

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RCUS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RCUS Butterfly Map → + Track RCUS →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -35.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RCUS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RCUS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RCUS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RCUS)

Health Care Rank #988 of 1015 ⚔️ PBH vs RCUS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RCUS vs. PBH, BHVN, PHVS, HCM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Arcus Biosciences Inc. (RCUS) ranks #988 by composite RQD confidence (19/100, grade E) and #231 by equity capitalization ($2.32B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while PBH leads on capital efficiency and profitability with 13.8% ROIC and 54.7% gross margin. PBH currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with RCUS at 19/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RCUS ACTIVE Arcus Biosciences Inc.	E	19/100	—	—	-35.0%	-1.87%	$2.32B	Benchmark Subject
PBH Prestige Consumer Healthcare Inc.	C	62/100	12.1x	54.7%	13.8%	+1.37%	$2.32B	/pbh-vs-rcus →
BHVN Biohaven Ltd.	D	44/100	—	—	-35.0%	-1.69%	$2.33B	/bhvn-vs-rcus →
PHVS Pharvaris N.V.	C-	59/100	—	—	—	0.00%	$2.34B	/phvs-vs-rcus →
HCM HUTCHMED (China) Limited	E	34/100	5.2x	—	-2.5%	+0.91%	$2.29B	/hcm-vs-rcus →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001724521 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Arcus Biosciences Inc. (RCUS) reported GAAP revenue of $33.0M (-35.3% vs. FY2024 revenue of $51.0M , and -10.8% cumulative change since FY2023) , GAAP net income of -$353.0M, operating cash flow of -$482.0M, and free cash flow of -$484.0M (-175.0% YoY). On the balance sheet, RCUS closed FY2025 with $1.14B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$33.0M	-$353.0M	-$482.0M	-$484.0M	$1.14B	—
FY2024 (FY)	2024-12-31	$51.0M	-$283.0M	-$170.0M	-$176.0M	$1.15B	—
FY2023 (FY)	2023-12-31	$37.0M	-$307.0M	-$306.0M	-$306.0M	—	—

3. RCUS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RCUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does RCUS compare to PBH and BHVN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for RCUS?

Where is RCUS trading relative to its 50-day, 200-day, and 52-week technical levels?

RCUS last traded at $17.85 (-1.87% on volume of 1,380,522 shares), positioning the stock -27.14% below its 50-day simple moving average ($24.50) and -27.53% below its 200-day simple moving average ($24.63). Across its 52-week range of $17.43 to $31.74, RCUS sits at the 2.9% percentile with a 14-day RSI of 31.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($15.62 to $20.08).

Direct Sub-Reports: RCUS RQD Cockpit RCUS 12M Forecast RCUS Earnings & Move RCUS Dividends & DRIP RCUS Insiders & 13F RCUS Whale Options RCUS Profit Sankey RCUS News & Why

ROARABLE RATING BRIEF • RQD 19/100 (E) ✓ SEC XBRL & RQD VERIFIED

RCUS — Arcus Biosciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Arcus Biosciences Inc. (RCUS) earns a live Roarable RQD composite score of 19/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $17.85 (-1.87% 1D, market capitalization $2.32B).

Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -20.42%.
Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (3/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Arcus Biosciences Inc. Is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company's market capitalization is $2.4B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Arcus Biosciences Inc. (RCUS) reported $33.0M in annual revenue (up from $51.0M in FY2024, -35.3% YoY) and -$353.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($37.0M revenue, -$307.0M net income) through FY2025, RCUS scaled operating cash flow to -$482.0M and free cash flow to -$484.0M, backed by $1.14B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 19/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -20.42% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $17.43 – $31.74 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), RCUS carries a macro regime beta of 1.00 and gross margin of —.

Key Question #1: Can RCUS sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $33.0M and free cash flow of -$484.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is RCUS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RCUS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Arcus Biosciences Inc. (RCUS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RCUS Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

How Investors Are Reacting To Arcus Biosciences (RCUS) Expansive New Casdatifan ARC-20 Kidney Cancer Data

Yahoo Finance report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Arcus Biosciences slides 20% on stock offering, kidney-cancer data (RCUS:NYSE)

Seeking Alpha report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Why is Arcus Biosciences stock sliding today?

Investing.com report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH AlphaStreet • 1d ago

Arcus Biosciences Drops 6.1% Amid Sector-Wide Selling

AlphaStreet report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investor's Business Daily • 1d ago

Arcus Reverses Course, Surging On Its Merck-Rivaling Cancer Reveal

Investor's Business Daily report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Price to book forward of Arcus Biosciences, Inc. – BOATS:RCUS

TradingView report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 1d ago

Arcus Biosciences stock falls on public offering announcement

Yahoo Finance report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead (NYSE:RCUS)

Seeking Alpha report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RCUS Bull vs. Bear Conversation Board — What's Your Call at $17.85?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RCUS 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $22.74 (+25.0%)

📌 Pinned Debate

Recent news flow cites a surge on kidney-cancer data and the price sits 6.7% above its 52-week low of $17.43.

Don't sleep on RCUS's setup in Health Care. Recent news flow cites a surge on kidney-cancer data and the price sits 6.7% above its 52-week low of $17.43.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (19/100) backs up the fundamental quality.

VolSurface_Trader 🐂 BULL

Both sides have a point here — RCUS's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $14.73 (-19.0%)

Spot @ $18.19

A -35% ROIC, -20.42% FCF yield, and a Piotroski F-Score of 1/9 point to sustained cash burn and weak fundamental quality.

Here is the bear case nobody on the bull side wants to address on RCUS: A -35% ROIC, -20.42% FCF yield, and a Piotroski F-Score of 1/9 point to sustained cash burn and weak fundamental quality.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.